Taysha Gene Therapies, Inc. (TSHA) free cash flow
Taysha Gene Therapies, Inc. (TSHA) generated free cash flow of -$93.83M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$81.60M. Figures as of 18 Nov 2026, 12:21 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Free cash flow, fiscal 2025
- -$93.83M
- Highest on record
- -$30.81Mfiscal 2020
- Lowest on record
- -$132.35Mfiscal 2021
- Fiscal years on record
- 62020–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Taysha Gene Therapies, Inc. free cash flow, in more detail
Across the 6 fiscal years on record (2020–2025), the highest was -$30.81M in fiscal 2020 and the lowest -$132.35M in fiscal 2021.
Free cash flow by fiscal year
Taysha Gene Therapies, Inc. free cash flow, year by year
| Fiscal year | Free cash flow | Change | Year ended |
|---|---|---|---|
| 2025 | -$93.83M | — | |
| 2024 | -$81.60M | — | |
| 2023 | -$80.39M | — | |
| 2022 | -$113.26M | — | |
| 2021 | -$132.35M | — | |
| 2020 | -$30.81M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.
How to read it
It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.
Taysha Gene Therapies, Inc., figure by figure
- Taysha Gene Therapies, Inc. market cap
- Taysha Gene Therapies, Inc. revenue
- Taysha Gene Therapies, Inc. earnings
- Taysha Gene Therapies, Inc. earnings per share (EPS)
- Taysha Gene Therapies, Inc. P/E ratio
- Taysha Gene Therapies, Inc. P/S ratio
- Taysha Gene Therapies, Inc. P/B ratio
- Taysha Gene Therapies, Inc. operating margin
- Taysha Gene Therapies, Inc. dividend
- Taysha Gene Therapies, Inc. shares outstanding
- Taysha Gene Therapies, Inc. total debt
- Taysha Gene Therapies, Inc. cash on hand
- Taysha Gene Therapies, Inc. total assets
- Taysha Gene Therapies, Inc. return on equity (ROE)
- Taysha Gene Therapies, Inc. return on invested capital (ROIC)
Taysha Gene Therapies, Inc. (TSHA) overview: price, valuation and scorecard
Taysha Gene Therapies, Inc. free cash flow: questions and answers
What is Taysha Gene Therapies, Inc.'s free cash flow?
Taysha Gene Therapies, Inc. (TSHA) generated free cash flow of -$93.83M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$81.60M.
What are the highest and lowest free cash flow figures on record for Taysha Gene Therapies, Inc.?
Across the 6 fiscal years on record (2020–2025), the highest was -$30.81M in fiscal 2020 and the lowest -$132.35M in fiscal 2021.
How is Taysha Gene Therapies, Inc.'s free cash flow calculated?
Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Taysha Gene Therapies, Inc. it is on record here for 6 fiscal years, 2020 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: free cash flow
All stocks guides →- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
- How a DCF valuation works, and why inputs swing it
A discounted cash flow (DCF) valuation estimates what a business is worth today by forecasting the cash it will produce and discounting each year's cash back at a required rate of return. Because most of the value lies far in the future, a one-point change in growth or discount rate can move the answer by a quarter.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Taysha Gene Therapies, Inc. (TSHA) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/TSHA/free-cash-flow
Underlying data: the company's filings with the SEC and Yahoo Finance.